A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor
Advanced curatively unresectable solid tumors failing standard therapy.
HCC: must have failed at least 1 line of standard therapy
Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)
Other solid tumours: must have failed at least 1 line of standard therapy
Subscribe to our mailing list to get the updates to your email inbox...